Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This is an extension study of Protocol CA194002 to allow 2 specific participants with basal
cell nevus syndrome in the CA194002 study at Princess Margaret Cancer Centre who are still
benefitting from the study drug BMS-833923 to continue receiving the study drug. This study
will continue to evaluate the safety and tolerability of BMS-833923 in these participants.